Prophylactic effect of liposomal N-acetylcysteine against LPS-induced liver injuries.
The aim of this study was to evaluate and compare the effectiveness of N-acetylcysteine (NAC) and liposomally-encapsulated NAC (L-NAC) in ameliorating the hepatotoxic effects of lipopolysaccharide (LPS). LPS, a major cell wall molecule of Gram-negative bacteria and the principal initiator of septic shock, causes liver injury in vivo that is dependent on neutrophils, platelets, and several inflammatory mediators, including tumour necrosis factor-alpha (TNF-alpha). Male Sprague-Dawley rats were pretreated intravenously with saline, plain liposomes (dipalmitoylphosphatidylcholine [DPPC]), NAC (25 mg/kg body weight), or L-NAC (25 mg/kg NAC body weight) and 4 h later were challenged intravenously with LPS (Escherichia coli O111:B4, 1.0 mg/kg body weight); animals were killed 20 h post-LPS challenge. Hepatic cell injury was evaluated by measuring the alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities in plasma. LPS-induced activation of the inflammatory response was evaluated by measuring the levels of myeloperoxidase activity and chloramine concentration in liver homogenates as well as TNF-alpha levels in plasma. The hepatic levels of lipid peroxidation products and non-protein thiols (NPSH) were used to assess the extent of involvement of oxidative stress mechanisms. In general, challenge of animals with LPS resulted in hepatic injuries, activation of the inflammatory response, decreases in NPSH levels and increases in the levels of lipid peroxidation products (malondialdehyde and 4-hydroxyalkenals). Pretreatment of animals with NAC or empty liposomes did not have any significant protective effect against LPS-induced hepatotoxicity. On the other hand, pretreatment of animals with an equivalent dose of L-NAC conferred protection against the liver injuries induced following LPS challenge. These data suggest that NAC when delivered as a liposomal formulation is a potentially more effective prophylactic pharmacological agent in alleviating LPS-induced liver injuries.
Alipour
Misagh
M
The Novel Drug and Vaccine Delivery Systems Facility, Laurentian University, Sudbury, Ontario, Canada.
Omri
Abdelwahab
A
Smith
Milton G
MG
Suntres
Zacharias E
ZE
D000111:Acetylcysteine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D001835:Body Weight; D002700:Chloramines / Q000032:analysis; D004195:Disease Models, Animal; D015227:Lipid Peroxidation / Q000187:drug effects / Q000276:immunology; D008070:Lipopolysaccharides / Q000008:administration & dosage / Q000037:antagonists & inhibitors; D008099:Liver / Q000187:drug effects* / Q000201:enzymology / Q000293:injuries*; D008239:Lysine / Q000031:analogs & derivatives* / Q000494:pharmacology; D008297:Male; D009929:Organ Size; D009195:Peroxidase / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D013438:Sulfhydryl Compounds / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
D002700:Chloramines; D008070:Lipopolysaccharides; C086501:N-acetylcysteine lysinate; D013438:Sulfhydryl Compounds; D014409:Tumor Necrosis Factor-alpha; D009195:Peroxidase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D008239:Lysine; C030816:chloramine; D000111:Acetylcysteine